Abstract: The invention provides an isolated nucleic acid molecule, designated as a kinase nucleic acid molecule, which encodes a novel protein kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing kinase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. The invention still further provides isolated 14790 proteins, fusion proteins, antigenic peptides and anti-kinase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The present invention relates to a newly identified human agmatinase-like arginase, designated “25312”. The invention also relates to polynucleotides encoding the agmatinase-like arginase. The invention further relates to methods using the agmatinase-like polypeptides and polynucleotides as a target for diagnosis and treatment in disorders mediated by or related to the agmatinase-like arginase. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the polypeptides and polynucleotides as a target.

Abstract: The invention provides an isolated nucleic acid molecule, designated as a kinase nucleic acid molecule, which encodes a novel protein kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing kinase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. The invention still further provides isolated 14790 proteins, fusion proteins, antigenic peptides and anti-kinase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The invention provides an isolated nucleic acid molecule, designated as a kinase nucleic acid molecule, which encodes a novel protein kinase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing kinase nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a kinase gene has been introduced or disrupted. The invention still further provides isolated 14790 proteins, fusion proteins, antigenic peptides and anti-kinase antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The present invention relates to a newly identified human agmatinase-like arginase, designated “25312”. The invention also relates to polynucleotides encoding the agmatinase-like arginase. The invention further relates to methods using the agmatinase-like polypeptides and polynucleotides as a target for diagnosis and treatment in disorders mediated by or related to the agmatinase-like arginase. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the polypeptides and polynucleotides as a target.

Abstract: The present invention relates to a newly identified human agmatinase-like arginase, designated “25312”. The invention also relates to polynucleotides encoding the agmatinase-like arginase. The invention further relates to methods using the agmatinase-like polypeptides and polynucleotides as a target for diagnosis and treatment in disorders mediated by or related to the agmatinase-like arginase. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the polypeptides and polynucleotides as a target.

Abstract: The invention provides isolated nucleic acids molecules, designated 32626 nucleic acid molecules, which encode novel UDP-glycosyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 32626 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 32626 gene has been introduced or disrupted. The invention still further provides isolated 32626 proteins, fusion proteins, antigenic peptides and anti-32626 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: The present invention relates to a newly identified human agmatinase-like arginase, designated “25312”. The invention also relates to polynucleotides encoding the agmatinase-like arginase. The invention further relates to methods using the agmatinase-like polypeptides and polynucleotides as a target for diagnosis and treatment in disorders mediated by or related to the agmatinase-like arginase. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the polypeptides and polynucleotides as a target.